Journal Article

PUBDB-2025-04837

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Pulmonary delivery of anti-infectives from natural sources: Development and characterization of liposomal sanggenon formulations

Schwarzinger, J. ; Bello, G. ; Tropin, T. ; Wölk, C.Extern* ; Blanchet, C.Extern*EMBL* ; Adelsberger, S. ; Hädrich, G. ; Rollinger, J. M. ; Grienke, U. ; Harvey, R. (Corresponding author)Extern* ; Dailey, L. A.

2025
Elsevier New York, NY [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1016/j.ejps.2025.107361  doi:10.3204/PUBDB-2025-04837

Abstract: Sanggenon C (SGC) and sanggenon D (SGD) are stereoisomeric natural products with promising anti-infective potential, especially against pathogens involved in acute respiratory infections. However, their bulky structures, poor aqueous solubility, and low oral bioavailability present major therapeutic challenges. Inhalation enables direct delivery to the site of infection while minimizing systemic exposure. Liposomal formulations DMPC:DMPG (2:1 w/w) of SGC and SGD, prepared via ethanol injection, achieved high drug loadings (> 3.5 mg/mL). Drug-lipid interactions were evaluated via DSC, Langmuir trough studies, SAXS, and cryo-TEM, showing incorporation of the compounds in the lipid bilayer. While stereochemistry-dependent differences were evident in vesicle size and thermotropic behavior, other biophysical data indicated that these differences were largely mitigated upon formulation. Liposomal formulations showed an excellent stability during nebulization with a vibrating mesh nebulizer (mass median aerodynamic diameters: 1.30–1.35 µm) and the high affinity of the compounds for the lipid bilayer resulted in a sustained in vitro release profile (8–9 % after 240 h). The retention of the drugs in the liposomes also significantly reduced cytotoxicity at 24 h compared to neat compounds. These findings highlight the importance of stereochemistry in drug-membrane interaction, yet their similar formulation performance suggests that both compound formulations are promising candidates for pulmonary anti-infective therapy.

---

Contributing Institute(s):

1. EMBL-User (EMBL-User)
2. EMBL (EMBL)

Research Program(s):

1. 6G3 - PETRA III (DESY) (POF4-6G3) (POF4-6G3)

Experiment(s):

1. PETRA Beamline P12 (PETRA III)

Appears in the scientific report 2025

---

Database coverage:
; ; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Chemical Reactions ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF < 5 ; Index Chemicus ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---